Article

pressherald.com on 2023-11-30 23:18

Drugmaker AbbVie to spend over $10 billion on ImmunoGen to juice its cancer-fighting treatment portfolio

Cheaper versions of the drugmaker’s all-time best seller, Humira, are cutting into its sales.

TOM MURPHY

Related news

AbbVie to buy leukemia drugmaker Pharmacyclics for $21B The Columbian
Sunnyvale , North Chicago
Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail bizjournals.com
Waltham
IAbbVie bolsters portfolio with $10.1 billion ImmunoGen buyout for cancer therapy invezz.com
Alvotech Files Suit Against AbbVie to Invalidate Humira Patent Portfolio jdsupra.com
Iceland , Arlington , Illinois
GlaxoSmithKline to spend $5.1B on cancer drugmaker Tesaro reviewtimes.com
Waltham
AbbVie makes $63B bid for Botox maker Allergan ocregister.com
Illinois , North Chicago , United States , Irvine , Ireland
AbbVie: Q3 Earnings Snapshot Merced Sun-Star
Wall Street , North Chicago
AbbVie: Q2 Earnings Snapshot Merced Sun-Star
Wall Street , North Chicago
AbbVie: Q4 Earnings Snapshot thenewstribune.com
Wall Street , North Chicago
GlaxoSmithKline to spend $5.1B on cancer drugmaker Tesaro - Mon, 03 Dec 2018 PST The Spokesman-Review
Waltham , China , Shanghai
AbbVie buys drugmaker Pharmacyclics in $21B deal USA today
Ireland
AbbVie beats Street 3Q forecasts dothaneagle.com
Wall Street , North Chicago
AbbVie Launches Large Debt Sale wsj.com
North Chicago
AbbVie meets 4Q profit forecasts seattletimes.com
Wall Street , North Chicago , Lake Bluff